| Bioactivity | JNJ 17029259 is an orally active and selective VEGF-R2 kinase inhibitor. JNJ 17029259 inhibits VEGF-mediated signal transduction. JNJ 17029259 has anti-angiogenic activity[1][2]. |
| Name | JNJ 17029259 |
| CAS | 314267-57-7 |
| Formula | C26H30N6O |
| Molar Mass | 442.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mohammed S. I. Makki, et al. Fluorine Substituted 1,2,4-Triazinones as Potential Anti-HIV-1 and CDK2 Inhibitors. Journal of Chemistry. 2014. Article ID 430573. [2]. Reuman M, et al. Scalable synthesis of the VEGF-R2 kinase inhibitor JNJ-17029259 using ultrasound-mediated addition of MeLi-CeCl3 to a nitrile. J Org Chem. 2008 Feb 1;73(3):1121-3. |
JNJ 17029259
CAS: 314267-57-7 F: C26H30N6O W: 442.56
JNJ 17029259 is an orally active and selective VEGF-R2 kinase inhibitor. JNJ 17029259 inhibits VEGF-mediated signal tran
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.